Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Enliven Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 8 filings
- 4 insiders, $11.8M in total
- Insiders trading
- 4
- Net value
- −$11.8M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Enliven Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | 38,000 | Sep 21, 2026 | 8 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | 25,000 | Sep 21, 2026 | 11 |
| Derynck Mika K | Director | 0 | Aug 6, 2026 | 2 |
| Kunkel Lori Anne | Director | 41,884 | Jul 8, 2026 | 4 |
| OrbiMed Advisors LLC | 10% Owner | 6,555,102Indirect | Jun 24, 2026 | 2 |
| OrbiMed Capital GP VII LLC | 10% Owner | 6,555,102Indirect | Jun 24, 2026 | 2 |
| OrbiMed Genesis GP LLC | 10% Owner | 6,555,102Indirect | Jun 24, 2026 | 2 |
| Heyman Richard A. | Director | 22,647Indirect | Feb 19, 2026 | 4 |
| Garland J. Scott | Director | – | Feb 17, 2026 | 2 |
| Gupta Rishi | Director | 7,663,349Indirect | Feb 17, 2026 | 1 |
| Bauer Jake | Director | 87,372 | Feb 17, 2026 | 1 |
| Ballal Rahul D. | Director | 22,341 | Feb 17, 2026 | 1 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 18,750 | Feb 17, 2026 | 7 |
| Patel Anish | CHIEF OPERATING OFFICER | 20,000 | Feb 17, 2026 | 5 |
| Fair Richard A. | PRESIDENT AND CEO | – | Dec 12, 2025 | 1 |
| Kintz Samuel | PRESIDENT AND CEO | 890,392Indirect | Nov 19, 2025 | 2 |
| Phillips Andrew John | Director | – | Feb 10, 2025 | 0 |
| Schwab Andrew J. | 10% Owner | 635,341Indirect | Feb 16, 2024 | 0 |
| Parmar Kush | 10% Owner | 635,341Indirect | Feb 16, 2024 | 0 |
| 5AM Opportunities I, L.P. | 10% Owner | 635,341Indirect | Feb 16, 2024 | 0 |
| 5AM Ventures VI, L.P. | 10% Owner | 635,341Indirect | Feb 16, 2024 | 0 |
| 5AM Opportunities I (GP), LLC | 10% Owner | 635,341Indirect | Feb 16, 2024 | 0 |
| 5AM Partners VI, LLC | 10% Owner | 635,341Indirect | Feb 16, 2024 | 0 |
| RA Capital Healthcare Fund LP | Other: Former 10% owner | 2,122,465Indirect | Feb 27, 2023 | 0 |
| Ra Capital Management, L.P. | Other: Former 10% owner | 2,122,465Indirect | Feb 27, 2023 | 0 |
| Kolchinsky Peter | Other: Former 10% owner | 2,122,465Indirect | Feb 27, 2023 | 0 |
| Shah Rajeev M. | Other: Former 10% owner | 2,122,465Indirect | Feb 27, 2023 | 0 |
| Commodore Capital LP | 10% Owner | 1,448,640Indirect | Feb 27, 2023 | 0 |
| Gray Michael | CFO & COO | 27,610 | Feb 22, 2023 | 0 |
| Leonard Braden Michael | 10% Owner | 1,767,774Indirect | Jan 5, 2023 | 0 |
| Goldfischer Carl | Director | – | Jun 3, 2022 | 0 |
| Mott David M | Director | 229,224 | Jun 3, 2022 | 0 |
| Bonita David P | Director, 10% Owner | 4,199,068Indirect | Jun 3, 2022 | 0 |
| Dalton Barbara | Director | – | Jun 3, 2022 | 0 |
| Conner Edward R. | Director | – | Jun 3, 2022 | 0 |
| Chin Mark | Director | 2,344,072Indirect | Jun 3, 2022 | 0 |
| Williams Laura A | Director | – | Jun 3, 2022 | 0 |
| Kerins Patrick J | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| Sandell Scott D | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| Baskett Forest | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| New Enterprise Associates 14, L.P. | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| NEA Partners 14, L.P. | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| Nea 14 GP, Ltd | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| Sonsini Peter W. | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| Florence Anthony A. Jr. | 10% Owner | 2,611,050 | Apr 7, 2022 | 0 |
| Attie Kenneth | SVP, CMO | 34,100 | Feb 1, 2022 | 0 |
| OrbiMed Capital LLC | Director, 10% Owner | 1,666,666Indirect | Jul 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 (view filing) | Feb 6 | 4 days | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | SSale | −5.00K | $29.04 | −$145.2K | −0.7%740.2K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Heyman Richard A.Director | SSale | −1.23K | $26.18 | −$32.2K | −5.2%22.6K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −45.0K | $26.17 | −$1.18M | −64.3%25.0K after | 10b5-1 |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −10.0K | $29.58 | −$295.8K | −16.4%51.0K after | |
| Mar 11, 2026 (view filing) | Mar 9-10 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −40.0K | $30.06 | −$1.20M | −61.5%25.0K after | 2 lots10b5-1 |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $27.76 | −$138.8K | −16.7%25.0K after | 10b5-1 |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −40.0K | $35.10 | −$1.40M | −61.5%25.0K after | 10b5-1 |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $47.67 | −$238.4K | −16.7%25.0K after | 3 lots10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $39.79 | −$199.0K | −16.7%25.0K after | 3 lots10b5-1 |
| Jun 9, 2026 (view filing) | Jun 5 | 4 days | Kunkel Lori AnneDirector | SSale | −10.0K | $34.54 | −$345.4K | −16.2%51.9K after | 3 lots10b5-1 |
| Jun 17, 2026 (view filing)7:45 PM ET | Jun 15 | 2 days | OrbiMed Advisors LLC and 2 others10% Owner | SSale | −281.4K | $45.02 | −$12.7M | −3.7%7.39M after | 2 lots |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $43.80 | −$219.0K | −16.7%25.0K after | 3 lots10b5-1 |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $43.80 | −$263.6K | −10.6%51.0K after | 3 lots10b5-1 |
| Jun 24, 2026 (view filing)7:19 PM ET | Jun 22 | 2 days | OrbiMed Advisors LLC and 2 others10% Owner | SSale | −860.1K | $45.36 | −$39.0M | −11.6%6.56M after | 4 lots |
| Jul 8, 2026 (view filing)5:15 PM ET | Jul 6 | 2 days | Kunkel Lori AnneDirector | SSale | −10.0K | $50.49 | −$504.9K | −19.3%41.9K after | 2 lots10b5-1 |
| Jul 21, 2026 (view filing)5:23 PM ET | Jul 17 | 4 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $52.67 | −$263.4K | −16.7%25.0K after | 5 lots10b5-1 |
| Jul 21, 2026 (view filing)5:24 PM ET | Jul 17 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $52.64 | −$316.8K | −11.6%46.1K after | 5 lots10b5-1 |
| Aug 6, 2026 (view filing)8:18 PM ET | Aug 4 | 2 days | Derynck Mika KDirector | SSale | −158.8K | $60.21 | −$9.56M | −100.0%0 after | 10b5-1 |
| Aug 19, 2026 (view filing)4:16 PM ET | Aug 17 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $58.59 | −$292.9K | −16.7%25.0K after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)4:17 PM ET | Aug 17 | 2 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $58.58 | −$352.6K | −13.1%40.0K after | 2 lots10b5-1 |
| Sep 21, 2026 (view filing)5:22 PM ET | Sep 17 | 4 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $50.35 | −$251.8K | −16.7%25.0K after | 3 lots10b5-1 |
| Sep 21, 2026 (view filing)5:23 PM ET | Sep 17 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $50.35 | −$303.0K | −13.7%38.0K after | 3 lots10b5-1 |